REYNO LEONARD 4
4 · C4 Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
C4 Therapeutics CMO Reyno Leonard Receives RSU Award
What Happened Reyno Leonard, Chief Medical Officer of C4 Therapeutics (CCCC), received a grant of 240,000 restricted stock units (RSUs) on Feb 13, 2026. On Feb 14, 2026, 30,950 shares were acquired upon vesting/settlement of previously disclosed RSUs. To cover tax withholding, 16,579 shares were surrendered at an effective withholding value of $1.89 per share (total $31,334). Net new shares added to Leonard’s holdings from the vesting event = 14,371 shares (30,950 acquired − 16,579 withheld).
Key Details
- Transactions reported: Feb 13, 2026 (RSU grant of 240,000 RSUs, $0.00 per share) and Feb 14, 2026 (30,950 shares acquired on vesting; 16,579 shares withheld for taxes at $1.89/share, $31,334).
- Grant vesting schedule (footnote): 120,000 RSUs vest in three equal annual installments beginning Feb 13, 2027 (first installment Feb 13, 2027); the other 120,000 RSUs vest in full on Feb 13, 2029, subject to possible performance‑based acceleration.
- Footnotes: the 30,950 shares reflect vesting of previously reported RSU grants (initially disclosed Feb 14, 2024 and Feb 18, 2025). The 16,579‑share disposition is tax withholding by the issuer, not an open‑market sale.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Filing timing: Form 4 was filed Feb 18, 2026 for transactions dated Feb 13–14, 2026. Form 4s are typically due within two business days of transactions, so this filing appears to have been submitted after that window.
Context RSU grants and subsequent withholding for taxes are common compensation events and do not by themselves indicate a change in the insider’s market view. The grant is an award (not an open‑market purchase or sale), and the acquisition on Feb 14 represents settlement of prior RSUs rather than an exercise requiring cash payment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-13+240,000→ 396,382 total - Exercise/Conversion
Common Stock
[F2]2026-02-14+30,950→ 396,382 total - Tax Payment
Common Stock
[F3]2026-02-14$1.89/sh−16,579$31,334→ 379,803 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- [F2]Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 14, 2024 and February 18, 2025.
- [F3]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.